Russia to participate in setting up of NMIZs
15 April 2013
The government is offering a host of incentives like exemption from capital gains tax and a liberalised labour and environment norms to promote these zones.
Rusnano asset and Pfizer to develop and market new drugs
11 April 2013
BIND Therapeutics, a biotech asset of Russia’s Rusnano, has inked an agreement with Pfizer, a global pharma major, on the joint development and sales of innovation drugs, including cancer ones, Rusnano announced .
EBRD supports Russian pharmaceutical industry
11 April 2013
A Russian-owned and managed pharmaceutical company, GEROPHARM-Bio, a subsidiary of OOO Geropharm, has obtained a five-year EBRD loan to finance part of the cost of expanding and modernising of its production plant at Obolensk in the Moscow region in order to help it comply with international standards.
Drug-company data vaults to be opened
09 April 2013
European agency will publish firms’ clinical-trial results.
International calls for the pharmaceutical industry to share the results of clinical trials have grown ever more intense amid revelations that high-profile companies have hidden crucial data on safety and efficacy. Now Europe is moving towards measures that would significantly increase disclosure of such data.
Rusnano Fund stimulates demand for nano products
08 April 2013
The Government of Kaluga Region and Rusnano’s Fund for Infrastructure and Educational Programs (FIEP) have launched a programme to stimulate demand for nanotech products in the region, the press service of the fund reports.
Here Are 3 Things Big Pharma Must Do To Survive - Joseph Jimenez
04 April 2013
After years of relative stability and high profits, things aren't looking particularly rosy for the pharmaceutical industry. Blockbuster drugs are losing patent protection, R&D efforts haven't paid off as hoped, and prices will come under pressure from the Affordable Care Act.
New Far East medical center may expect equipment from Rusnano or Japanese
02 April 2013
Rusnano, Russia’s nanotech giant, is ready to join as a co-investor whatever private-public partnership (PPP) may form to equip the new high tech medical center to soon open at Vladivostok-based Far East Federal University (FEFU), the first such center in the Primorsky region in Russia’s Far East
The revenue of Rusnano nanotech centers in 2012 is 365M RUR
01 April 2013
According to Rusnano, the revenue of Russian nanotech centers that were launched in 2012 under the auspices of the Fund for infrastructure and educational programs of Rusnano, JSC totaled 365M RUR.
Russian investment vehicle sets sights on innovative drugs
29 March 2013
Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. Rusnano has been ploughing hundreds of millions of dollars into pioneering pharma companies with the aim of growing Russia’s domestic drug production, and making a tidy return by licensing drugs to foreign partners.
U.S. struggles with pharmaceutical goals in Asia trade talks
29 March 2013
The United States is striving to find an appropriate balance in Asia-Pacific free trade talks between providing strong patent and data protections for U.S. drug manufacturers and ensuring poor people have access to medicine, a U.S. trade negotiator said on Thursday.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
The Russian government will support the development and production of modern drugs
16 September 2024
Russia’s Long-Lasting Flu Vaccine Undergoes Trials
16 September 2024
Moscow to Launch Digitalization Course for Students
12 September 2024
Russia has created an oral drug aimed at treating obesity and diabetes
12 September 2024